Showing results (21-30 of 146) with videos related to
Sort By:
Pageof 15
Cancer Research|April 15, 1990
Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factorJ Y Blay, M C Favrot, S Negrier, et al.Therapie|November 7, 1998
[Gene therapy: a review 6 years after the first trials in man. Round Table No 6 at Giens XIII]M C FavrotEuropean Journal of Cancer & Clinical Oncology|November 1, 1989
Clinical value of N-myc oncogene amplification in 52 patients with neuroblastoma included in recent therapeutic protocolsV Combaret, Q Wang, M C Favrot, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Indication and limits of megatherapy and bone marrow transplantation in high-risk neuroblastoma: a single centre analysis of prognostic factorsR Ladenstein, M Favrot, C Lasset, et al.Journal of Biological Response Modifiers|April 1, 1990
Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinomaM C Favrot, V Combaret, S Negrier, et al.British Journal of Cancer|June 1, 1989
Immunological detection of neuroblastoma cells in bone marrow harvested for autologous transplantationV Combaret, M C Favrot, B Kremens, et al.Human Gene Therapy|June 1, 1992
Retroviral gene therapy and its application in oncohematologyY Merrouche, M C FavrotBone Marrow Transplantation|August 1, 1987
Detection of minimal malignant cell infiltration in the bone marrow of patients with solid tumours, non-Hodgkin lymphomas and leukaemiasM C Favrot, P HervéLa Revue Du Praticien|November 1, 1993
[Neuroblastoma. Current clinical and therapeutic aspects. Contributions of modern biology]O Hartmann, M C FavrotBritish Journal of Cancer|January 1, 1997
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinomaC Bain, Y Merrouche, I Puisieux, et al.Pageof 15